Sanofi India Ltd vs Vasundhara Rasayans Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3402 as of 05 May 15:30 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Vasundhara Rasayans Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Vasundhara Rasayans Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Vasundhara Rasayans Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Vasundhara Rasayans Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Vasundhara Rasayans Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Vasundhara Rasayans Ltd changed from 16.22 % to 14.96 % over 5 quarters. This represents a CAGR of -6.26% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Vasundhara Rasayans Ltd

Vasundhara Rasayans Limited was incorporated in March, 1987.
The Company is the leading manufacturer and exporter of Antacids therapeutic category of Active Pharmaceutical Ingredients with annual capacity of about 1500 MT of powder or its equivalent products.
It started its operation in year 1990 with an Antacid API facility offering product in paste, powder and micronised grade of powder. The plant is located on National Highway between Mumbai and Goa in an Industrial Zone called Mahad which is about 170 KMS from Mumbai and about 125 KMS from the NSICT /JNPT Ports Mumbai.
In addition to the API manufacturing Vasundhara is also having an API intermediate plant to handle organic products with its state of the art specialised Friedel Craft reaction facility. The manufacturing area is maintained as per GMP standards.

FAQs for the comparison of Sanofi India Ltd and Vasundhara Rasayans Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Vasundhara Rasayans Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Vasundhara Rasayans Ltd is 41 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Vasundhara Rasayans Ltd?

The stock performance of Sanofi India Ltd and Vasundhara Rasayans Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Vasundhara Rasayans Ltd?

As of May 5, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Vasundhara Rasayans Ltd stock price is INR ₹132.0.

How do dividend payouts of Sanofi India Ltd and Vasundhara Rasayans Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Vasundhara Rasayans Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.